Summary A total of 474 adult patients with malignant glioma (astrocytoma) grade 3 or 4 were randomised into an MRC study (BR2) comparing 45 Gy (in 20 fractions over 4 weeks) with 60 Gy (in 30 fractions over 6 weeks) of radiotherapy given post-operatively. Using 2:1 randomisation, 318 patients were allocated the 60 Gy course and 156 the 45 Gy course. Adjuvant chemotherapy was not given. The results show that a 60 Gy course produces a modest lengthening of progression-free and overall survival. They suggest a statistically significant prolongation of median survival from 9 months in the 45 Gy group to 12 months in the 60 Gy group (hazard ratio = 0.75, x2 = 7.36, d.f. = 1, P = 0.007). Over 80% of patients reported no morbidity from the radiotherapy, and there was no evidence of increased short-term morbidity in the higher dose group. Late morbidity was not assessed. A prognostic index defined in a previous MRC study was validated in this new cohort. It identifies a group of patients (20% of the total) with a 2 year survival rate of 28% (95% confidence interval 19% to 38%). It was apparent that the survival advantage to the higher dose was maintained even in the poorest prognostic groups defined by this index.
Although post-operative radiotherapy has been shown to improve survival in patients with high grade supratentorial astrocytoma (Walker et al., 1978) , the optimum radiation dose has not been established. In 1982 when this randomised trial was proposed the tendency in the UK was to use a dose in the region of 45 Gy in 20 fractions over 4 weeks, as in the previous Medical Research Council study of misonidazole (MRC, 1983) . However in the US particularly, a higher dose of 60 Gy in 30 fractions over 6 weeks was often standard. The accumulated evidence at that time that a higher dose improved survival came from retrospective analyses of several large series using different doses (Walker et al., 1979; Salazar et al., 1979) and not from randomised trials. Thus there was no clear evidence as to the optimum dose in the post-operative treatment of such patients.
In April 1983, the MRC Brain Tumour Working Party initiated a multicentre study comparing these two radiotherapy doses in the treatment of adult patients with grade 3 and 4 supratentorial astrocytoma. The results of this study, and an independent evaluation of the prognostic index derived from the previous study (MRC, 1983) , are presented here.
Design
The trial aimed to compare the effects of post-operative radiotherapy at two dose levels -45 Gy and 60 Gy total dose -in the treatment of adult patients with grade 3 or 4 supratentorial astrocytoma with respect to time to clinical deterioration and overall survival.
Following surgery, patients satisfying the eligibility criteria below were randomised to treatment by a telephone call to the MRC Cancer Trials Office, with the exception of one overseas centre where sealed envelopes were provided. Ran- Adjuvant chemotherapy was not employed, but treatment at relapse was at the clinician's discretion.
Statistical methods
Survival curves were calculated using the Kaplan-Meier method, and the overall differences in survival curves examined using the logrank test (Peto et al., 1977) . All comparisons of treatment effect were carried out on an 'intention to treat' basis. To estimate the improvement in median survival due to treatment after adjusting for prognostic factors, the hazard ratios was used as an estimate of the ratio of median survival times (Freedman, 1982) . Cox's proportional hazards regression model (Tibshirani, 1982) was used to adjust for the influence of prognostic factors when assessing treatment effect.
Results
Between April 1983 and September 1988, 474 patients (74 more than the target recruitment) were randomised into the study from 15 centres in the UK and one in South Africa (Table I ). The pathology reference panel ruled 31 patients ineligible on the basis of incorrect histology (12 in group 1 and 19 in group 2). Since the pathology review was blind to treatment assignment, these patients were excluded from this report. Otherwise, all patients thought eligible at the time of randomisation were included in the analysis. Thus 443 patients -144 allocated 45 Gy and 299, 60 Gy are included. The minimum follow-up time amongst these patients is 14 months.
Pre-radiotherapy characteristics Table II shows the pre-treatment characteristics of these 443 patients by their allocated treatment. The treatment groups are well balanced with respect to most of these characteristics, although there is some imbalance in the age distributions. The effect of this imbalance on the assessment of treatment efficacy is discussed later.
Treatment Table III shows the extent of deviations from the protocol specified radiotherapy. 'Exact adherence' is defined as a dose of 45 Gy in 20 fractions over 4 to 5 weeks in group 1, and a total dose of 60 Gy in 30 fractions over 6 to 7 weeks in group 2. A 'major deviation' was defined as a total dose in excess of 5 Gy more or less than the protocol specifications. These occurred mainly when treatment was terminated early because of the patients deteriorating condition and included one patient in group 1 and three in group 2 who were considered too ill to receive any radiotherapy.
Minor deviations therefore comprised small changes in dose or fractionation, or delays in completing radiotherapy that were mainly a result of administrative problems, holidays or machine breakdown.
Overall exact compliance was 80%, with little difference in Side effects reported at the end of treatment are described in Table IV (2) 1Oc (3) 13 (3) 'Each side effect seen in only one patient. bBronchopneumonia, wound breakdown, hallucinations. CGI bleeding, otitis, visual deterioration, chest pain, CVA, lung infection, glycosuria, dizziness, Cushiongoid, raised ICP. Figure 1 shows the survival curves by allocated treatment. At 12 months, the survival rates in group 1 and group 2 were 29% and 39% respectively, the corresponding rates at 18 months being 11% and 18% (Table V) Group 1 (45 Gy), curves for the six prognostic groups. The two 'best' groups combined comprise just over 20% of the total and have a 2 year survival rate of 28% (95% CI 19%, 38%).
It is clearly of interest to know if the advantage to the higher dose is maintained in the poorer prognosis patients. To investigate this, patients were divided into three groups on the basis of their prognostic index score and a logrank analysis of treatment effect carried out within each of the three groups. The problems of subgroup analysis must be recognised, particularly here where the overall treatment effect is small, and the chance of obtaining spurious results in smaller subgroups high. Table VII summarises the results of these exploratory analyses. A significant improvement in survival was still apparent in the poorest prognostic group, which had an overall 2 year survival rate of 3% (X2LR = 5.7, d.f. = 1, P = 0.02). While noting the limitations of subgroup analyses mentioned above, this data provides no evidence of lack of efficacy of the higher dose in the poorest prognosis patients.
Discussion
Radiation dose This trial has addressed the important question of the optimum dose of external beam radiotherapy in high grade gliomas. It has demonstrated that a small but significant survival gain is achieved when 60 Gy is compared with the 45 Gy dose schedule. There have been numerous previous reports on the optimum radiation dose (Chang et al., 1983; Onoyoma et al., 1976; Walker et al., 1979; Salazar et al., 1979; Scanlon & Taylor, 1979; Rutten et al., 1981) . The key report from the US Brain Tumour Study Group (Walker et al., 1979) , analysed the relationship between increasing survival and increasing doses of radiotherapy on 621 patients entered into three successive studies. Patients were divided into three groups with median total doses of 50, 55 or 60 Gy. The median survival times (MST) were 28, 36 and 42 weeks respectively. The increase in MST from 50 to 60 Gy was highly significant. However, it is important to again note that patients were not randomised, but retrospectively allocated to the three dose groups.
Salazar et al. (1979) also reviewed 100 patients, grouped retrospectively, with median doses of 50, 60 and 75 Gy. Each dose group was analysed in subgroups according to tumour grade (3 or 4). The study was not randomised and numbers, particularly in the high dose group, were small. A trend to improved survival with higher dose was noted. In contrast, a subsequent joint Radiation Therapy Oncology Group (RTOG) and Eastern Cooperative Oncology Group (ECOG) randomised study (Chang et al., 1983 ) compared 148 patients allocated 60 Gy given over 6 to 7 weeks whole brain irradiation with 105 given that dose plus a booster dose of 10 Gy to the tumour volume (in 1-2 further weeks). There were no differences seen in overall survival between the two groups. Thus the value of external beam doses higher than 60 Gy remains in question.
The total radiation dose that may be delivered to brain tumours is limited by the normal tissue toxicity (Sheline, 1986) . Methods of increasing the effective tumour dose without increase in normal tissue damage have been investigated recently. These include interstitial implantation of removable high activity sources of iodine-125 (Leibel et al., 1989 ), or irridium-192 (Chun et al., 1989 ; endocavitary intra-operative cobalt -60 sources (Kumar et al., 1989) , and stereotactic external beam 'radiosurgery' using a linear accelerator (Hartmann et al., 1985) . Boron-neutron capture as originally proposed by Sweet (1951) , is also under reinvestigation. Altered fractionation schedules employing multiple daily fractions have yielded conflicting results (Davis, 1989) . In general, no improvement in survival over conventional treatment was seen. In one study a significant advantage to multiple daily fractions was reported (Shin et al., 1985) but the MST in the control group was only 27 weeks, placing the overall conclusion in some doubt.
Treatment volume
The optimum treatment volume remains uncertain. In this study an initial volume of most of the supratentorial brain widely encompassing the tumour was selected. A more closely defined boost volume was then selected in the high dose group. This practice varied in the other studies discussed above with the initial treatment ranging from whole brain to a boost with a 1-2 cm margin around the radiologically defined tumour. Early work by Concannon et al. (1960) suggested wide infiltration in high grade gliomas and this has determined subsequent radiation practice with its emphasis on whole brain radiation. However, a recent BTCG study confirmed the efficacy of wide field irradiation followed by a boost as compared to whole brain irradiation (Shapiro et al., 1989) .
Most recent trends attempting to achieve higher doses have resulted in reduction of target volumes, but difficulties in defining that volume remain. Thus when the extent of tumour and 'oedema' as seen on immediate antemortem CT examination were related to the post mortem findings, they were shown to underestimate considerably the extent of the tumour (Halperin et al., 1989) . In a pattern of failure study, Wallner et al. (1989) , concluded that partial brain irradition was feasible. They observed that 18/32 (56%) of unifocal
recurrences occurred within 1 cm of the pre-surgery enhancing tumour edge as seen on CT, and 25/32 (78%) within 2cm. In our present study the protocol defined a tumour margin of 1 cm in the boost volume. This may have resulted in some marginal recurrences. The data in the two post mortem studies are however based on relatively small numbers.
Adjuvant chemotherapy
The role of adjuvant chemotherapy remains under actiye investigation but awaits identification of more effective drugs and combinations than are presently available. In this trial chemotherapy was only employed when deemed appropriate on relapse. Only 12 patients in the low-dose group (9%) received chemotherapy on relapse and 21 (7%) in the higher dose group. Many groups use adjuvant chemotherapy as part of the initial treatment strategy. This may confer a small survival advantage over control non-chemotherapy groups. A review of published trials (Stenning et al., 1987) suggests the benefit from addition of a nitrosourea may be of the same order as that resulting from use of the higher radiotherapy dose used here. The overall results in this study may therefore have been improved if a nitrosourea containing adjuvant regimen had been employed. In the present MRC high grade glioma study (MRC/BR5) this role of adjuvant chemotherapy is being explored.
Prognostic factors
The importance of prognostic factors in patients with high grade gliomas has been emphasised in reports from several groups (Walker et al., 1978; Walker et al., 1980; Chang et al., 1983; EORTC, 1981; MRC, 1990) . These have included age of patient, performance status, duration of symptoms and tumour grade. Other less important features are blood group, pretreatment white cell and platelet counts and level of consciousness after surgery (Green et al., 1983 ). An analysis of 417 patients in the MRC Brain Tumour Working Party misonidazole study (MRC/BR1) identified age, clinical performance status, length of history of fits and extent of surgery as the only independent prognostic variables (MRC, 1990) . The predictive value of the index proposed in that study has been confirmed in the present study (Table VI and Figure 2 ). Such an index may be of value in the design of future study protocols and routine clinical treatment decisions.
It is of interest that the advantage of the higher dose was maintained in the poorer prognostic group. However, the short overall median survival time in the latter groups casts doubt of the value of routine use of such prolonged treatments in such patients.
Conclusions
This trial has demonstrated that a modest progression-free and overall survival gain is achieved by using 60 Gy as opposed to 45 Gy in the post-operative treatment of grades 3 and 4 astrocytoma. The estimated gain corresponds to a 3 month increase in median survival time, from 9 months in patients receiving the lower dose to 12 months in those receiving the higher dose.
The results of this trial, in conjunction with the prognostic index, may aid the rational selection of patients for prolonged intensive courses of therapy in a disease with such poor overall survival results. 
